Potential interaction between ritonavir and carbamazepine.

Article Details

Citation
Copy to clipboard

Kato Y, Fujii T, Mizoguchi N, Takata N, Ueda K, Feldman MD, Kayser SR

Potential interaction between ritonavir and carbamazepine.

Pharmacotherapy. 2000 Jul;20(7):851-4.

PubMed ID
10907977 [ View in PubMed
]
Abstract

Ritonavir (RTV), a protease inhibitor, and carbamazepine (CBZ), an anticonvulsant, were administered concurrently to a patient who had human immunodeficiency virus infection and epilepsy. The combination resulted in elevated serum concentrations of CBZ, with accompanying vomiting, vertigo, and transient liver dysfunction. After discontinuing RTV and reducing the dosage of CBZ, the serum concentration of CBZ returned to the optimal range, symptoms subsided, and liver function returned to baseline. Carbamazepine is metabolized in the liver to a large extent by the cytochrome P450 (CYP) system, especially CYP3A4, 2C8, and 1A2, whereas RTV is metabolized primarily by CYP3A and is a potent inhibitor of this enzyme. Careful clinical monitoring may help prevent adverse drug interactions when these drugs are administered concurrently.

DrugBank Data that Cites this Article

Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
CarbamazepineCytochrome P450 2C8ProteinHumans
Unknown
Substrate
Inducer
Details
Drug Interactions
DrugsInteraction
Integrate drug-drug
interactions in your software